Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) PT at $31.67

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $31.6667.

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald began coverage on Avalo Therapeutics in a research report on Friday, August 15th. They issued an “overweight” rating on the stock. Cowen began coverage on Avalo Therapeutics in a report on Friday, September 5th. They issued a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avalo Therapeutics in a research report on Saturday, September 27th. HC Wainwright increased their price objective on Avalo Therapeutics from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Finally, TD Cowen assumed coverage on shares of Avalo Therapeutics in a research note on Friday, September 5th. They issued a “buy” rating on the stock.

Avalo Therapeutics Price Performance

NASDAQ:AVTX opened at $13.67 on Friday. The company’s 50 day moving average is $10.80 and its 200-day moving average is $7.06. Avalo Therapeutics has a 12 month low of $3.39 and a 12 month high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.49). Sell-side analysts forecast that Avalo Therapeutics will post -19.07 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AVTX. RWA Wealth Partners LLC bought a new stake in shares of Avalo Therapeutics in the first quarter valued at about $2,505,000. Affinity Asset Advisors LLC lifted its position in shares of Avalo Therapeutics by 19.3% in the 1st quarter. Affinity Asset Advisors LLC now owns 657,154 shares of the company’s stock worth $5,264,000 after acquiring an additional 106,389 shares during the period. Nantahala Capital Management LLC bought a new stake in shares of Avalo Therapeutics in the 1st quarter worth approximately $7,209,000. ADAR1 Capital Management LLC acquired a new stake in shares of Avalo Therapeutics during the 1st quarter worth approximately $80,000. Finally, Allostery Investments LP increased its position in shares of Avalo Therapeutics by 46.1% during the first quarter. Allostery Investments LP now owns 107,141 shares of the company’s stock valued at $858,000 after purchasing an additional 33,827 shares during the period. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.